Africa life sciences intelligence
Africa Life Sciences Intelligence
A standing record of developments in African life sciences that change how regulated business is structured, contracted and governed, with the legal and commercial consequence set out plainly.
Who this is for
Written for legal counsel, clinical operations and study start-up leads, research contracts and grants teams, and corporate development teams. Nothing in this section is legal advice, and nothing in it indicates that the firm acts for, has been approached by, or has any relationship with any organisation named in it.
How entries are verified
Each entry states the date on which its facts were last verified against the primary source. Developments are assessed as at that verification date and are not monitored for change thereafter. Entries are retained as dated reference material.
Method
Entries are added when a development materially changes how an arrangement has to be structured, not on a publishing schedule. Facts are drawn from primary sources and cited. Analysis is identified as analysis and addresses the category of arrangement, not the affairs of any named party.
2 entries
-
Manufacturing and technology transfer Published 1 August 2026 Last verified 1 August 2026
Development-bank financing into South African vaccine manufacturing: what the contract stack has to carry
A $15m development-bank loan into a Cape Town multi-vaccine facility, alongside a syndicate and five separate technology partners: a structure where the financing, the transfer arrangements and the quality obligations all have to line up.
Read the analysis -
Market entry and partnerships Published 1 August 2026 Last verified 1 August 2026
The non-binding MoU as a market-entry instrument: what it does and does not do
A government-level cooperation agreement signed as an expressly non-binding MoU: a common opening instrument in African market entry, and a common source of internal misalignment about what has actually been agreed.
Read the analysis